NYSE:CTLT - Catalent Stock Price, Price Target & More

Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."

Catalent (NYSE:CTLT) released its quarterly earnings results on Tuesday, May, 1st. The company reported $0.41 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.35 by $0.06. The business had revenue of $627.90 million for the quarter, compared to the consensus estimate of $610.47 million. Catalent had a net margin of 2.62% and a return on equity of 21.76%. The company's quarterly revenue was up 17.9% on a year-over-year basis. During the same period last year, the firm earned $0.38 earnings per share. View Catalent's Earnings History.

Catalent is scheduled to release their next quarterly earnings announcement on Monday, August, 27th 2018. View Earnings Estimates for Catalent.

Catalent updated its FY18 earnings guidance on Tuesday, May, 1st. The company provided earnings per share (EPS) guidance of $1.57-$1.74 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.67. The company issued revenue guidance of $2.42-$2.48 billion, compared to the consensus revenue estimate of $2.45 billion.

14 brokerages have issued 12-month target prices for Catalent's stock. Their predictions range from $38.00 to $50.00. On average, they expect Catalent's stock price to reach $45.8182 in the next year. View Analyst Ratings for Catalent.

Some companies that are related to Catalent include Mylan (MYL), BioMarin Pharmaceutical (BMRN), GRIFOLS S A/S (GRFS), UCB (UCBJF), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Valeant Pharmaceuticals Intl (VRX), BeiGene (BGNE), Genmab A/S (GNMSF), Alkermes (ALKS) and SAGE Therapeutics (SAGE).

Media coverage about CTLT stock has trended somewhat positive recently, according to Accern. Accern rates the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Catalent earned a news sentiment score of 0.15 on Accern's scale. They also gave news articles about the company an impact score of 46.19 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Catalent's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (11.45%), JPMorgan Chase & Co. (3.21%), Champlain Investment Partners LLC (2.72%), American Century Companies Inc. (2.15%), Earnest Partners LLC (1.90%) and Northern Trust Corp (1.52%). Company insiders that own Catalent stock include Blackstone Management Associat, Christine Dolan, Donald E Morel, Jr, John R Chiminski, Sharon Johnson, Uwe Roehrhoff and William Downie. View Institutional Ownership Trends for Catalent.

CTLT stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Millennium Management LLC, BNP Paribas Arbitrage SA, Hood River Capital Management LLC, Dimensional Fund Advisors LP, JPMorgan Chase & Co., Loomis Sayles & Co. L P and Carillon Tower Advisers Inc.. Company insiders that have sold Catalent company stock in the last year include Christine Dolan, John R Chiminski and William Downie. View Insider Buying and Selling for Catalent.

CTLT stock was bought by a variety of institutional investors in the last quarter, including Champlain Investment Partners LLC, Wells Fargo & Company MN, Prudential Financial Inc., GW&K Investment Management LLC, Impax Asset Management LLC, American Century Companies Inc., Segall Bryant & Hamill LLC and Mackay Shields LLC. Company insiders that have bought Catalent stock in the last two years include Donald E Morel, Jr and Uwe Roehrhoff. View Insider Buying and Selling for Catalent.

Shares of CTLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CTLT stock can currently be purchased for approximately $41.12.

Catalent has a market capitalization of $5.53 billion and generates $2.08 billion in revenue each year. The company earns $109.80 million in net income (profit) each year or $1.35 on an earnings per share basis. Catalent employs 10,800 workers across the globe.

Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The company can be reached via phone at 732-537-6200 or via email at [email protected]